Vivanza Biosciences Ltd

Vivanza Biosciences Ltd

Vivanza Biosciences Ltd has informed that Regulation 23(9) of SEBI (LODR) Regulations, 2015 regarding submission of disclosures of related party transactions for the half year ended on September 30, 2026, does not apply to the company due to its paid-up equity share capital and net worth not exceeding Rs. 10 Crores and Rs. 25 Crore, respectively. The company's paid-up equity share capital and net worth as on March 31, 2026 are Rs. 4,00,00,000 and Rs. 4,39,53,502.15, respectively.

Vivanza Biosciences Ltd

Vivanza Biosciences Ltd has scheduled a Board Meeting on November 3, 2026, to consider and approve unaudited standalone and consolidated Financial Results for the quarter and Half year ended September 30, 2026.

Vivanza Biosciences Ltd

Vivanza Biosciences Ltd has confirmed that it has not raised any further funds through public issue, rights issue, or preferential issue, making the submission of a statement of deviation or variation under Regulation 32 of SEBI LODR Regulations, 2015, not applicable to the company.

Vivanza Biosciences Ltd

Vivanza Biosciences Ltd has received a compliance certificate from Purva Share Registry (I) Pvt Ltd and Share Transfer Agent (RTA) for the quarter ended September 30, 2026, confirming the dematerialization of securities and listing on stock exchanges.

Vivanza Biosciences Ltd

Vivanza Biosciences Ltd has announced the closure of its trading window for the quarter and half year ending 30th September, 2026, in accordance with SEBI regulations, from 1st October, 2026, until 48 hours after the declaration of unaudited financial results.

Vivanza Biosciences Ltd

Vivanza Biosciences Ltd has announced the completion of dispatch of the Annual Report for the Financial Year 2025-26 along with the Notice convening the 44th Annual General Meeting of the Company, scheduled to be held on September 11, 2026. The company has also made available a remote e-voting facility to the shareholders, with a cut-off date for determining the eligibility of shareholders to vote at the AGM.

Vivanza Biosciences Ltd

Vivanza Biosciences Ltd has announced its Annual Report for the Financial Year 2025-2026, along with the Notice of the 44th Annual General Meeting. The meeting will be held on September 11, 2026, through video conferencing. The report includes audited standalone and consolidated financial statements, as well as reports from the Board of Directors and Independent Auditor.

Vivanza Biosciences Ltd

Vivanza Biosciences Ltd has announced the 44th Annual General Meeting (AGM) and Annual Report for the financial year 2025-26. The AGM will be held on September 11, 2026, through video conferencing. The company has enclosed the Notice of the 44th AGM and Annual Report, which are available on the company's website.

Vivanza Biosciences Ltd

Vivanza Biosciences Ltd held its Board Meeting on August 17, 2026, and approved various business proposals, including Director's Report, Secretarial Audit Report, and related party transactions. The company also approved the adoption of a new Memorandum of Association and Articles of Association, and increased borrowing limits.

Vivanza Biosciences Ltd

Vivanza Biosciences Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/08/2026 to consider and approve various business matters, including the Director's Report and Secretarial Audit Report for the Financial Year 2025-26, and to convene the 44th Annual General Meeting.

Vivanza Biosciences Ltd

Vivanza Biosciences Ltd has confirmed that it has not raised any further funds through public issues, rights issues, or preferential issues, making the submission of a statement of deviation or variation under Regulation 32 of SEBI (LODR) Regulations, 2015, not applicable.

Vivanza Biosciences Ltd

Vivanza Biosciences Ltd has published a newspaper advertisement in compliance with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, announcing the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026.

Vivanza Biosciences Ltd

Vivanza Biosciences Ltd has approved its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, and other items.

Vivanza Biosciences Ltd

Vivanza Biosciences Ltd has approved its unaudited standalone and consolidated financial results for the quarter ended 30th June, 2026, and other items at its board meeting on 7th August, 2026.

Vivanza Biosciences Ltd

Vivanza Biosciences Ltd approved unaudited standalone and consolidated financial results for Q1 FY2026-27, along with year-to-date figures for the period from April 1, 2026, to June 30, 2026.

Vivanza Biosciences Ltd

Vivanza Biosciences Ltd has rescheduled its Board Meeting from August 1st to August 7th, 2026, to consider unaudited financial results and other items.

Vivanza Biosciences Ltd

Vivanza Biosciences Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/08/2026 to consider and approve unaudited standalone and consolidated financial results along with limited review report for the quarter ended on June 30, 2026.